FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032835525> ?p ?o ?g. }

• W3032835525 endingPage "356" @default.
• W3032835525 startingPage "352" @default.
• W3032835525 abstract "ObjectiveTo evaluate the clinical effects of Shendan-Huoxue capsule combined with etoposide soft capsule in the treatment of advanced ovarian cancer in the elderly patients.MethodsA total of 94 elderly patients with ovarian cancer who met the inclusion criteria were divided into 2 groups using random number table method, 47 patients in each group. All patients were given conventional chemotherapy, the control group was given etoposide soft capsule on this basis, and the observation group was given Shendan-Huoxue capsule on the basis of the control group. Both groups were treated for 12 weeks and followed up for 2 years. Ovarian cancer specificity scale version 4 (FACT-OV4) was used to evaluate the life quality of the patients, flow cytometry was used to detect the level of CD3+ , CD4+ , CD8+ , CD19+ . Ovarian cancer was detected by CT, toxic and side effects during treatment were recorded, and clinical efficacy was evaluated.ResultsThe total effective rate in the observation group was 87.2% (41/47), and that in the control group was 70.2% (33/47). The difference between the two groups was statistically significant (χ2=3.782, P=0.041). The 1-year survival rate was 87.2% (41/47) and 2-year survival rate was 61.7% (29/47) in the observation group, and 74.4% (35/47) and 53.2% (25/47) in the control group, respectively. The 1-year and 2-year survival rates of the two groups were statistically significant (χ2=4.109, 4.268 respectively, P=0.038, 0.036). The median total survival time in the observation group and the control group was 13.9 months (95% IC 12.4-16.2) and 10.3 months (95% IC 8.2-14.1), respectively. The median total survival time in the observation group was significantly longer than that in the control group (P<0.05). After treatment, scores of social/family status and functional status in the observation group were significantly higher than those in the control group (t values were 3.711 and 4.003, respectively, P<0.05), and scores of additional attention, physiological status and emotional status were significantly lower than those in the control group (t values were 4.335, 4.522 and 4.202, respectively, P<0.05). After treatment, the levels of CD3+ , CD4+ , CD8+ , CD19+ in the observation group were all higher than those in the control group (t values were 7.217, 7.129, 7.434 and 6.521, respectively, P<0.01 or P<0.05). During the period of treatment , the incidence of skin rash, liver function injury, decreased white blood cell count, nausea and vomiting, peripheral neuropathy, diarrhea and abdominal pain in the observation group were significantly lower than those in the control group (χ2 values were 4.114, 4.782, 4.521, 3.911, 3.931, 3.821, P<0.05, respectively).ConclusionsThe Shendan-Huoxue capsule combined with etoposide soft capsule can improve the survival time of elderly patients with advanced ovarian cancer, improve the body immunity, reduce toxic and side effects, and the clinical effect is better than conventional chemotherapy.Key words: Ovarian neoplasms; Aged; Shendan-Huoxue capsule; Etoposide soft capsules; Immunomodulation; Survivorship; Quality of life; Drug-related side effects and adverse reactions" @default.
• W3032835525 created "2020-06-05" @default.
• W3032835525 creator A5029427429 @default.
• W3032835525 creator A5086919343 @default.
• W3032835525 creator A5089773076 @default.
• W3032835525 date "2019-04-30" @default.
• W3032835525 modified "2023-09-24" @default.
• W3032835525 title "Clinical effects of Shendan-Huoxue capsule combined with etoposide soft capsules in the treatment of advanced ovarian carcinoma in elderly patients" @default.
• W3032835525 doi "https://doi.org/10.3760/cma.j.issn.1673-4246.2019.04.008" @default.
• W3032835525 hasPublicationYear "2019" @default.
• W3032835525 type Work @default.
• W3032835525 sameAs 3032835525 @default.
• W3032835525 citedByCount "0" @default.
• W3032835525 crossrefType "journal-article" @default.
• W3032835525 hasAuthorship W3032835525A5029427429 @default.
• W3032835525 hasAuthorship W3032835525A5086919343 @default.
• W3032835525 hasAuthorship W3032835525A5089773076 @default.
• W3032835525 hasConcept C121608353 @default.
• W3032835525 hasConcept C126322002 @default.
• W3032835525 hasConcept C141071460 @default.
• W3032835525 hasConcept C2776694085 @default.
• W3032835525 hasConcept C2778119113 @default.
• W3032835525 hasConcept C2778778583 @default.
• W3032835525 hasConcept C2780427987 @default.
• W3032835525 hasConcept C59822182 @default.
• W3032835525 hasConcept C71924100 @default.
• W3032835525 hasConcept C86803240 @default.
• W3032835525 hasConcept C90924648 @default.
• W3032835525 hasConceptScore W3032835525C121608353 @default.
• W3032835525 hasConceptScore W3032835525C126322002 @default.
• W3032835525 hasConceptScore W3032835525C141071460 @default.
• W3032835525 hasConceptScore W3032835525C2776694085 @default.
• W3032835525 hasConceptScore W3032835525C2778119113 @default.
• W3032835525 hasConceptScore W3032835525C2778778583 @default.
• W3032835525 hasConceptScore W3032835525C2780427987 @default.
• W3032835525 hasConceptScore W3032835525C59822182 @default.
• W3032835525 hasConceptScore W3032835525C71924100 @default.
• W3032835525 hasConceptScore W3032835525C86803240 @default.
• W3032835525 hasConceptScore W3032835525C90924648 @default.
• W3032835525 hasIssue "4" @default.
• W3032835525 hasLocation W30328355251 @default.
• W3032835525 hasOpenAccess W3032835525 @default.
• W3032835525 hasPrimaryLocation W30328355251 @default.
• W3032835525 hasRelatedWork W2304079920 @default.
• W3032835525 hasRelatedWork W2317585947 @default.
• W3032835525 hasRelatedWork W2347876928 @default.
• W3032835525 hasRelatedWork W2355606060 @default.
• W3032835525 hasRelatedWork W2355797253 @default.
• W3032835525 hasRelatedWork W2359491391 @default.
• W3032835525 hasRelatedWork W2362935652 @default.
• W3032835525 hasRelatedWork W2368630149 @default.
• W3032835525 hasRelatedWork W2370575436 @default.
• W3032835525 hasRelatedWork W2377142518 @default.
• W3032835525 hasRelatedWork W2382266066 @default.
• W3032835525 hasRelatedWork W2386598636 @default.
• W3032835525 hasRelatedWork W2392840903 @default.
• W3032835525 hasRelatedWork W2981829938 @default.
• W3032835525 hasRelatedWork W3028729912 @default.
• W3032835525 hasRelatedWork W3028920844 @default.
• W3032835525 hasRelatedWork W3029607776 @default.
• W3032835525 hasRelatedWork W3032507643 @default.
• W3032835525 hasRelatedWork W3032683303 @default.
• W3032835525 hasRelatedWork W3081565865 @default.
• W3032835525 hasVolume "41" @default.
• W3032835525 isParatext "false" @default.
• W3032835525 isRetracted "false" @default.
• W3032835525 magId "3032835525" @default.
• W3032835525 workType "article" @default.